Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 10, 2022
Reporting Period: Single event date (May 10, 2022)
Business Context: The Company is an emerging growth company focused on immunology. This filing reports a specific scientific event rather than periodic financial results.
Key Financial Metrics
This Form 8-K does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes
There are no material financial changes reported in this document. The filing discloses a non-financial event regarding the presentation of scientific data.
Outlook, Commentary, and Risks
- Scientific Event: On May 10, 2022, the Company announced that Professor Lesley Probert, Ph.D., Head of the Department of Immunology at the Hellenic Pasteur Institute in Athens, Greece, will present data on the effects of tumor necrosis factor (TNF) in Multiple Sclerosis (MS).
- Event Details: The presentation is occurring at the 3rd European Conference on Neuroinflammation in London.
- Legal Disclaimer: The information in this report and the attached press release (Exhibit 99.1) is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. It shall not be incorporated by reference into other registration statements unless expressly set forth by specific reference.
Investor Verification Checklist
- Verify the content of the attached press release (Exhibit 99.1) for specific data points regarding TNF and MS.
- Confirm the Company's status as an emerging growth company and its implications for financial reporting standards.
- Review subsequent filings for any financial impact or clinical trial updates resulting from the conference presentation.